<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36851614</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>31</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Persistent SARS-CoV-2 Infection, EBV, HHV-6 and Other Factors May Contribute to Inflammation and Autoimmunity in Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">400</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v15020400</ELocationID><Abstract><AbstractText>A novel syndrome called long-haul COVID or long COVID is increasingly recognized in a significant percentage of individuals within a few months after infection with SARS-CoV-2. This disorder is characterized by a wide range of persisting, returning or even new but related symptoms that involve different tissues and organs, including respiratory, cardiac, vascular, gastrointestinal, musculo-skeletal, neurological, endocrine and systemic. Some overlapping symptomatologies exist between long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Very much like with long ME/CFS, infections with herpes family viruses, immune dysregulation, and the persistence of inflammation have been reported as the most common pattern for the development of long COVID. This review describes several factors and determinants of long COVID that have been proposed, elaborating mainly on viral persistence, reactivation of latent viruses such as Epstein-Barr virus and human herpesvirus 6 which are also associated with the pathology of ME/CFS, viral superantigen activation of the immune system, disturbance in the gut microbiome, and multiple tissue damage and autoimmunity. Based on these factors, we propose diagnostic strategies such as the measurement of IgG and IgM antibodies against SARS-CoV-2, EBV, HHV-6, viral superantigens, gut microbiota, and biomarkers of autoimmunity to better understand and manage this multi-factorial disorder that continues to affect millions of people in the world.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vojdani</LastName><ForeName>Aristo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2925-9334</Identifier><AffiliationInfo><Affiliation>Immunosciences Lab, Inc., Los Angeles, CA 90035, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cyrex Laboratories, LLC, Phoenix, AZ 85034, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vojdani</LastName><ForeName>Elroy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Regenera Medical, Los Angeles, CA 90025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saidara</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maes</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road, Pathumwan, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015654" MajorTopicYN="Y">Herpesvirus 6, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EBV</Keyword><Keyword MajorTopicYN="N">HHV-6</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)</Keyword><Keyword MajorTopicYN="N">viral reactivation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>28</Day><Hour>1</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36851614</ArticleId><ArticleId IdType="pmc">PMC9967513</ArticleId><ArticleId IdType="doi">10.3390/v15020400</ArticleId><ArticleId IdType="pii">v15020400</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sun Y., Dong Y., Wang L., Xie H., Li B., Chang C., Wand F.-S. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. J. Autoimmun. 2020;112:102473. doi: 10.1016/j.jaut.2020.102473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102473</ArticleId><ArticleId IdType="pmc">PMC7180376</ArticleId><ArticleId IdType="pubmed">32439209</ArticleId></ArticleIdList></Reference><Reference><Citation>Setiati S., Harimurti K., Safitri E.D., Ranakusuma R.W., Saldi S.R.F., Azwar M.K., Marsigit J., Pitoyo Y., Widyaningsih W. Risk factors and laboratory test results associated with severe illness and mortality in COVID-19 patients: A systematic review. Acts Med. Indones. 2020;52:227&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">33020334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kifer D., Bugada D., Villar-Garcia J., Gudelj I., Menni C., Sudre C., Vuckovic F., Ugrina I., Lorini L.F., Posso M., et al. Effects of environmental factors on severity and mortality of COVID-19. Front. Med. 2021;7:607786. doi: 10.3389/fmed.2020.607786.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.607786</ArticleId><ArticleId IdType="pmc">PMC7855590</ArticleId><ArticleId IdType="pubmed">33553204</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Vojdani E., FRosenberg A.Z., Shoenfeld Y. The role of exposomes in the pathophysiology of autoimmune diseases II: Pathogens. Pathophysiology. 2022;29:243&#x2013;280. doi: 10.3390/pathophysiology29020020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathophysiology29020020</ArticleId><ArticleId IdType="pmc">PMC9231084</ArticleId><ArticleId IdType="pubmed">35736648</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappaport S.M., Smith M.T. Epidemiology, environment and disease risks. Science. 2010;330:460&#x2013;461. doi: 10.1126/science.1192603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1192603</ArticleId><ArticleId IdType="pmc">PMC4841276</ArticleId><ArticleId IdType="pubmed">20966241</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeulen R., Scymanski E.L., Barabasi A.L., Miller G.W. The exposome and health: Where chemistry meets biology. Science. 2020;367:392&#x2013;396. doi: 10.1126/science.aay3164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aay3164</ArticleId><ArticleId IdType="pmc">PMC7227413</ArticleId><ArticleId IdType="pubmed">31974245</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue J.K., Franco N.M., McCulloch D.J., McDonald D., Magedson A., Wolf C.R., Chu H.Y. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw. Open. 2021;4:e210830. doi: 10.1001/jamanetworkopen.2021.0830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F., Perego E. How and why patients made long COVID. Soc. Sci. Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S., Merad M. Pathological sequelae of long-haul COVID. Nat. Immunol. 2022;23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;Court C., Buxton M., Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Jahdhami I., Al-Naamani K., Al-Mawali A. The post-acute COVID-19 syndrome (long COVID) Oman Med. J. 2021;36:e220. doi: 10.5001/omj.2021.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.5001/omj.2021.91</ArticleId><ArticleId IdType="pmc">PMC7838343</ArticleId><ArticleId IdType="pubmed">33537155</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E., Janvier P., Kherabi Y., Le Bot A., Hamon A., Gouze H., Doucet L., Berkani S., Oliosi E., Mallart E., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020;81:e4&#x2013;e6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deeks S.G. Early clues regarding the pathogenesis of long COVID. Trends Immunol. 2022;43:268&#x2013;270. doi: 10.1016/j.it.2022.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hadrawi D.S., Al-Rubaye H.T., Almulla A.F., Al-Hakeim H.K., Maes M. Lowered oxygen saturation and increased body temperature in acute COVID-19 largely predict chronic fatigue syndrome and affective symptoms due to Long COVID: A precision nomothetic approach. Acta Neuropsychiatr. 2022;22:1&#x2013;12. doi: 10.1017/neu.2022.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/neu.2022.21</ArticleId><ArticleId IdType="pubmed">36134517</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong T.L., Weitzer D.J. Long COVID and myalgic enchepalomyelitis/chronic fatigue syndrome (MW/CFS)&#x2014;A systematic review and comparison of clinical presentation and symptomatology. Medicina. 2021;57:418. doi: 10.3390/medicina57050418.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050418</ArticleId><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman K.J., Murovska M., Pheby D., Zalewski P. Our evolving understanding of ME/CFS. Medicina. 2021;57:200. doi: 10.3390/medicina57030200.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57030200</ArticleId><ArticleId IdType="pmc">PMC7996879</ArticleId><ArticleId IdType="pubmed">33652622</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendergrast T., Brown A., Sunnquist M., Jantke R., Newton J.L., Strand E.B., Jason L.A. Housebound versus nonhousebound patients with myalgic encephalomyelitis and chronic fatigue syndrome. Chronic Illn. 2016;12:292&#x2013;307. doi: 10.1177/1742395316644770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1742395316644770</ArticleId><ArticleId IdType="pmc">PMC5464362</ArticleId><ArticleId IdType="pubmed">27127189</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu L., Valencia I.J., Garvert D.W., Montoya J.G. Onset patterns and course of myalgic encephalomyelitis/chronic fatigue syndrome. Front. Pediatr. 2019;7:12. doi: 10.3389/fped.2019.00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00012</ArticleId><ArticleId IdType="pmc">PMC6370741</ArticleId><ArticleId IdType="pubmed">30805319</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G., Anderson G., Galecki P., Berk M., Maes M. A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior. BMC Med. 2013;11:64. doi: 10.1186/1741-7015-11-64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-64</ArticleId><ArticleId IdType="pmc">PMC3751187</ArticleId><ArticleId IdType="pubmed">23497361</ArticleId></ArticleIdList></Reference><Reference><Citation>Straus S.E., Tosato G., Armstrong G., Lawley T., Preble O.T., Henle W., Davey R., Pearson G., Epstein J., Brus I., et al. Persistence illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann. Intern. Med. 1985;102:7&#x2013;16. doi: 10.7326/0003-4819-102-1-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-102-1-7</ArticleId><ArticleId IdType="pubmed">2578268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai K., Kawai A. Studies on the relationship between chronic fatigue syndrome and Epstein-Barr virus in Japan. Intern. Med. 1992;31:313&#x2013;318. doi: 10.2169/internalmedicine.31.313.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.31.313</ArticleId><ArticleId IdType="pubmed">1319246</ArticleId></ArticleIdList></Reference><Reference><Citation>Sairenji T., Yamanishi K., Tachibana Y., Bertoni G., Kurata T. Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. Intervirology. 1995;38:269&#x2013;273. doi: 10.1159/000150450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000150450</ArticleId><ArticleId IdType="pubmed">8724857</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron B., Flamand L., Juwana H., Middledorp J., Naing Z., Rawlinson W., Ablashi D., Lloyd A. Serological and virological investigation of the role of the herpesviruses EBV, CMV, and HHV-6 in post-infective fatigue syndrome. J. Med. Virol. 2010;62:1684&#x2013;1688. doi: 10.1002/jmv.21873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.21873</ArticleId><ArticleId IdType="pubmed">20827765</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox B.S., Alharshawi K., Mena-Palomo I., Lafuse W.P., Ariza M.E. EBV/HHV-6A dUTPases contribute to myalgic encephalomyelitis/chronic fatigue syndrome pathophysiology by enhancing Tfh cell differentiation and extrafollicular activities. JCI Insight. 2022;11:e158193. doi: 10.1172/jci.insight.158193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.158193</ArticleId><ArticleId IdType="pmc">PMC9220958</ArticleId><ArticleId IdType="pubmed">35482424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza M.E. Myalgic encephalomyelitis/chronic fatigue syndrome: The human herpesviruses are back. Biomolecules. 2021;11:185. doi: 10.3390/biom11020185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11020185</ArticleId><ArticleId IdType="pmc">PMC7912523</ArticleId><ArticleId IdType="pubmed">33572802</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Schneider A.M., Mehta A., Sade-Feldman M., Kays K.R., Gentili M., Charland N.C., Gonye A.L.K., Gushterova I., Khanna H.K., et al. SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes. J. Clin. Investig. 2021;131:e148635. doi: 10.1172/JCI148635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI148635</ArticleId><ArticleId IdType="pmc">PMC8245177</ArticleId><ArticleId IdType="pubmed">34196300</ArticleId></ArticleIdList></Reference><Reference><Citation>Silberry V.G.R., Rowe P. Pediatric long COVID and myalgic encephalomyelitis/chronic fatigue syndrome. Ped. Inf. Dis. 2022;41:e139&#x2013;e141. doi: 10.1097/INF.0000000000003477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003477</ArticleId><ArticleId IdType="pmc">PMC8919937</ArticleId><ArticleId IdType="pubmed">35121715</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard-Jones A.R., Burgner D.P., Crawford N.W., Goeman E., Gray P.E., Hsu P., Kuek S., McMullan B.J., Tosif S., Wurzel D., et al. COVID-19 in children. II: Pathogenesis, disease spectrum and management. J. Pediatr. Child. Health. 2022;58:46&#x2013;53. doi: 10.1111/jpc.15811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpc.15811</ArticleId><ArticleId IdType="pmc">PMC8662268</ArticleId><ArticleId IdType="pubmed">34694037</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim H.K., Al-Rubaye H.T., Al-Hadrawi D.S., Almulla A.F., Maes M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: A proof of concept and mechanism study. Mol. Psychiatry. 2022;24:1&#x2013;15. doi: 10.1038/s41380-022-01836-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01836-9</ArticleId><ArticleId IdType="pmc">PMC9589528</ArticleId><ArticleId IdType="pubmed">36280755</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze J.L., Aschenbrenner A.C. COVID-19 and the human innate immune system. Cell. 2021;184:1671&#x2013;1692. doi: 10.1016/j.cell.2021.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.029</ArticleId><ArticleId IdType="pmc">PMC7885626</ArticleId><ArticleId IdType="pubmed">33743212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumi T., Harada K. Immune response to SARS-CoV-2 in severe disease and long COVID-19. iScience. 2022;25:104723. doi: 10.1016/j.isci.2022.104723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.104723</ArticleId><ArticleId IdType="pmc">PMC9251893</ArticleId><ArticleId IdType="pubmed">35813874</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin D.E. Why does viral RNA sometimes persist after recovery from acute infections? PLoS Biol. 2022;20:e3001687. doi: 10.1371/journal.pbio.3001687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001687</ArticleId><ArticleId IdType="pmc">PMC9191737</ArticleId><ArticleId IdType="pubmed">35648781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasuga Y., Zhu B., Jang K.-J., Yoo J.-S. Innate immune sensing of coronavirus and viral evasion strategies. Exp. Mol. Med. 2021;53:723&#x2013;736. doi: 10.1038/s12276-021-00602-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00602-1</ArticleId><ArticleId IdType="pmc">PMC8099713</ArticleId><ArticleId IdType="pubmed">33953325</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Li S., Pan Y., Qin L., Yang S., Tan D., Hu Y., Knoll M.D., Wang X., Wang L., et al. An immunocompetent patient with high neutralizing antibody titers who shed COVID-18 virus for 169 days&#x2014;China, 2020. China CDC Wkly. 2021;3:688&#x2013;691. doi: 10.46234/ccdcw2021.163.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2021.163</ArticleId><ArticleId IdType="pmc">PMC8393007</ArticleId><ArticleId IdType="pubmed">34594968</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A., Zlitni S., Brooks E.F., Vance S.E., Dahlen A., Hedlin H., Park R.M., Han A., Schmidtke D.T., Verma R., et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3:371&#x2013;387. doi: 10.1016/j.medj.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A., Koch R., Jukic A., Pfister A., Meyer M., R&#xf6;ssler A., Kimpel J., Adolph T.E., Tilg H. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163:495&#x2013;506.e8. doi: 10.1053/j.gastro.2022.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmani A., Dino G., Leso V., Montecucco A., Vitturi B.N.K., Iavicoli I., Durando P. Duration of SARS-CoV-2 shedding and infectivity in the working population: A systematic review and meta-analysis. Med. Lav. 2022;113:e2022014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9073762</ArticleId><ArticleId IdType="pubmed">35481581</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung C.C.L., Goh D., Lim X., Tien T.Z., Lim J.C.T., Lee J.N., Tan B., Tay Z.E.A., Wan W.Y., Chen E.X. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut. 2022;71:226&#x2013;229. doi: 10.1136/gutjnl-2021-324280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324280</ArticleId><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs J.J.L. Persistent SARS-CoV-2 infections contribute to long COVID. Med. Hypotheses. 2021;149:110538. doi: 10.1016/j.mehy.2021.110538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2021.110538</ArticleId><ArticleId IdType="pmc">PMC7884250</ArticleId><ArticleId IdType="pubmed">33621843</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonnet A., Engelmann I., Moreau A.-S., Garcia B., Six S., El Kalioubie A., Robriquet L., Hober D., Jourdain M. High incidence of Epstein-Barr virus, cytomegalovirus and human-herpes 6 reactivation in critically ill patients with COVID-19. Infect. Dis. Now. 2021;51:296&#x2013;299. doi: 10.1016/j.idnow.2021.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC7816954</ArticleId><ArticleId IdType="pubmed">33495765</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubchenko S., Kril I., Nadizhko O., Matsyura O., Chopyak V. Herpesvirus infections and post-COVID-19 manifestations: A pilot observational study. Rheumatol. Int. 2022;42:1523&#x2013;1530. doi: 10.1007/s00296-022-05146-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05146-9</ArticleId><ArticleId IdType="pmc">PMC9159383</ArticleId><ArticleId IdType="pubmed">35650445</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover K., Higginbotham K. StatPearls. StatPearls Publishing LLC; Treasure Island, FL, USA: 2022. Epstein Barr Virus.</Citation><ArticleIdList><ArticleId IdType="pubmed">32644711</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasa S., Nora-Krukle Z., Henning N., Eliassen E., Shikova E., Harrer T., Scheibenbogen C., Murovska M., Prusty B.K., European Network on ME/CFS (EUROMENE) Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome {ME/CFS) J. Transl. Med. 2018;16:268. doi: 10.1186/s12967-018-1644-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1644-y</ArticleId><ArticleId IdType="pmc">PMC6167797</ArticleId><ArticleId IdType="pubmed">30285773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadinoto V., Shapiro M., Sun C.C., Thorley-Lawson D.A. The dynamics of EBV shedding implicates a central role for epithelial cells in amplifying viral output. PLoS Pathog. 2009;5:e1000496. doi: 10.1371/journal.ppat.1000496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000496</ArticleId><ArticleId IdType="pmc">PMC2698984</ArticleId><ArticleId IdType="pubmed">19578433</ArticleId></ArticleIdList></Reference><Reference><Citation>Agut H. Deciphering the clinical impact of acute human herpesvirus 6 (HHV-6) infections. J. Clin. Virol. 2011;52:164&#x2013;171. doi: 10.1016/j.jcv.2011.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2011.06.008</ArticleId><ArticleId IdType="pubmed">21782505</ArticleId></ArticleIdList></Reference><Reference><Citation>Borza C.M., Hutt-Fletcher L.M. Alternative replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat. Med. 2002;8:594&#x2013;599. doi: 10.1038/nm0602-594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0602-594</ArticleId><ArticleId IdType="pubmed">12042810</ArticleId></ArticleIdList></Reference><Reference><Citation>Aimola G., Beythien G., Aswad A., Kaufer B.B. Current understanding of human herpesvirus 6 (HHV-6) chromosomal integration. Antivir. Res. 2020;176:104720. doi: 10.1016/j.antiviral.2020.104720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104720</ArticleId><ArticleId IdType="pubmed">32044155</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma D., Church T.M., Swaminathan S. Epstein-Barr virus lytic replication induxces ACE2 expression and enhances SARS-CoV-2 pseudotyped virus entry in epithelial cells. J. Virol. 2021;95:e0019221. doi: 10.1128/JVI.00192-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00192-21</ArticleId><ArticleId IdType="pmc">PMC8316011</ArticleId><ArticleId IdType="pubmed">33853968</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolucci S., Cassaniti I., Novazzi F., Fiorina L., Piralla A., Commoli G., Bruno R., Maserati R., Gulminetti R., Novati S., et al. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int. J. Infect. Dis. 2021;104:315&#x2013;319. doi: 10.1016/j.ijid.2020.12.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.12.051</ArticleId><ArticleId IdType="pmc">PMC7833117</ArticleId><ArticleId IdType="pubmed">33359064</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J.E., Okyay R.A., Licht W.E., Hurley D.J. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10:763. doi: 10.3390/pathogens10060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Balandraud N., Roudier J. Epstein-Barr virus and rheumatoid arthritis. Jt. Bone Spine. 2018;85:165&#x2013;170. doi: 10.1016/j.jbspin.2017.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2017.04.011</ArticleId><ArticleId IdType="pubmed">28499895</ArticleId></ArticleIdList></Reference><Reference><Citation>Drosos A.A., Pelechas E., Voiulgari P.V. Long COVID from rheumatology perspective: A simple mimicker or promoter of autoimmunity? Clin. Rheumatol. 2022;41:957&#x2013;958. doi: 10.1007/s10067-022-06092-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06092-4</ArticleId><ArticleId IdType="pmc">PMC8831874</ArticleId><ArticleId IdType="pubmed">35147823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapkota H.R., Nune A. Long COVID from rheumatology perspective&#x2014;A narrative review. Clin. Rheumatol. 2022;41:337&#x2013;348. doi: 10.1007/s10067-021-06001-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-06001-1</ArticleId><ArticleId IdType="pmc">PMC8629735</ArticleId><ArticleId IdType="pubmed">34845562</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan R., Mao S.Q., Gu T.L., Zhong F.D., Gong M.L., Hao L.M., Yin F.Y., Dong C.Z., Zhang L.N. Preliminary analysis of the association between methylation of the ACE2 promoter and essential hypertension. Mol. Med. Rep. 2017;15:3905&#x2013;3911. doi: 10.3892/mmr.2017.6460.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.6460</ArticleId><ArticleId IdType="pubmed">28440441</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichelberg M.R., Welch R., Guidry J.T., Ali A., Ohashi M., Makielski K.R., McChesney K., Van Sciver N., Lambert P.F., Keles S., et al. Epstein-Barr virus infection promotes epithelial cell growth by attenuating differentiation-dependent exit from the cell cycle. mBio. 2019;10:e01332. doi: 10.1128/mBio.01332-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01332-19</ArticleId><ArticleId IdType="pmc">PMC6703421</ArticleId><ArticleId IdType="pubmed">31431547</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams M.V., Cox B., Ariza M.E. Herpesviruses dUTPases: A new family of pathogen-associated molecular pattern (PAMP) proteins with implications for human disease. Pathogens. 2017;6:2. doi: 10.3390/pathogens6010002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens6010002</ArticleId><ArticleId IdType="pmc">PMC5371890</ArticleId><ArticleId IdType="pubmed">28036046</ArticleId></ArticleIdList></Reference><Reference><Citation>Doitsh G., Galloway N.L.K., Geng X., Yang Z., Monroe K.M., Zependa O., Hunt P.W., Hatano H., Sowinski S., Munoz-Arias I., et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014;505:509&#x2013;514. doi: 10.1038/nature12940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12940</ArticleId><ArticleId IdType="pmc">PMC4047036</ArticleId><ArticleId IdType="pubmed">24356306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.C., Chan J., Clement M.-V., Pervaiz S. Functional proteomics of resveratrol-induced colon cancer cell apoptosis: Caspase-6-mediated cleavage of lamin A is a major signaling loop. Proteomics. 2006;6:2386&#x2013;2394. doi: 10.1002/pmic.200500366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.200500366</ArticleId><ArticleId IdType="pubmed">16518869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M., Shen J., Zhan J., Yu Y. dUTP pyrophosphatase, its appearance in extracellular compartment may serve as a potential biomarker for N-methyl-N&#x2019;-nitro-N-nitrosoguanadine exposure in mammalian cells. Proteomics. 2006;6:3001&#x2013;3007. doi: 10.1002/pmic.200500767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.200500767</ArticleId><ArticleId IdType="pubmed">16619294</ArticleId></ArticleIdList></Reference><Reference><Citation>Riza M.E., Rivailler P., Glaser R., Chen M., Williams M.V. Epstein-Barr virus encoded dUTPase containing exosomes modulate innate and adaptive immune responses in human dendritic cells and peripheral blood mononuclear cells. PLoS ONE. 2014;8:e69827</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3718799</ArticleId><ArticleId IdType="pubmed">23894549</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutler B. Interferences, questions and possibilities in Toll-like receptor signaling. Nature. 2004;430:257&#x2013;263. doi: 10.1038/nature02761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02761</ArticleId><ArticleId IdType="pubmed">15241424</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T., Akira S. Innate immune recognition of viral infection. Nat. Immunol. 2006;7:131&#x2013;137. doi: 10.1038/ni1303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1303</ArticleId><ArticleId IdType="pubmed">16424890</ArticleId></ArticleIdList></Reference><Reference><Citation>Guggemoos S., Hangel D., Hamm S., Heit A., Bauer S., Adler H. TLR9 contributes to the antiviral immunity during gamma herpesvirus infection. J. Immunol. 2008;80:438&#x2013;443. doi: 10.4049/jimmunol.180.1.438.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.1.438</ArticleId><ArticleId IdType="pubmed">18097045</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Yin H., Zhao M., Lu Q. TLR2 and TLR4 in autoimmune diseases: A comprehensive review. Clin. Rev. Allergy Immunol. 2014;47:136&#x2013;147. doi: 10.1007/s12016-013-8402-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-013-8402-y</ArticleId><ArticleId IdType="pubmed">24352680</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato A., Linehan M.M., Iwasaki A. Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells. Proc. Natl. Acad. Sci. USA. 2006;103:17343&#x2013;17348. doi: 10.1073/pnas.0605102103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0605102103</ArticleId><ArticleId IdType="pmc">PMC1859932</ArticleId><ArticleId IdType="pubmed">17085599</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehme K.W., Guerrero M., Compton T. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J. Immunol. 2006;177:7094&#x2013;7102. doi: 10.4049/jimmunol.177.10.7094.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.10.7094</ArticleId><ArticleId IdType="pubmed">17082626</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudreault E., Fiola S., Olivier M., Gosselin J. Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J. Virol. 2007;81:8016&#x2013;8024. doi: 10.1128/JVI.00403-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00403-07</ArticleId><ArticleId IdType="pmc">PMC1951286</ArticleId><ArticleId IdType="pubmed">17522215</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza M.E., Glaser R., Williams M.V. Human herpesviruses-encoded dUTPases: A family of proteins that modulate dendritic cell function and innate immunity. Front. Microbiol. 2014;5:504. doi: 10.3389/fmicb.2014.00504.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2014.00504</ArticleId><ArticleId IdType="pmc">PMC4176148</ArticleId><ArticleId IdType="pubmed">25309527</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza M.E., Glaser R., Kaumaya P.T.P., Jones C., Williams M. The Epstein-Barr virus (EBV)-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway. J. Immunol. 2009;182:851&#x2013;859. doi: 10.4049/jimmunol.182.2.851.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.182.2.851</ArticleId><ArticleId IdType="pubmed">19124728</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldman W.J., Williams M.V., Lemeshow S.A., Binkley P., Guttridge D., Kiecolt-Glaser J.K., Knight D.A., Ladner K.J., Glaser R. Epstein-Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages in contact with endothelial cells: Evidence for depression-induced atherosclerotic risk. Brain Behav. Immun. 2008;22:215&#x2013;223. doi: 10.1016/j.bbi.2007.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2007.07.007</ArticleId><ArticleId IdType="pmc">PMC2245868</ArticleId><ArticleId IdType="pubmed">17845840</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin P., Williams M.V., Klimas N.G., Fletcher M.A., Varnes Z., Ariza M.E. Myalgic encephalomyelitis/chronic fatigue syndrome and Gulf War illness patients exhibit increased humoral responses to the Herpesviruses-encoded dUTPase: Implications in disease pathophysiology. J. Med. Virol. 2017;89:1636&#x2013;1645. doi: 10.1002/jmv.24810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24810</ArticleId><ArticleId IdType="pmc">PMC5513753</ArticleId><ArticleId IdType="pubmed">28303641</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukocheva O.A., Maksoud R., Beeraka N.M., Madhunapantula S.V., Sinelnikov M., Nikolenko V.N., Neganova N.E., Klochkov S.G., Kamal M.A., Staines D.R., et al. Analysis of postCOVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome. J. Adv. Res. 2022;40:179&#x2013;196. doi: 10.1016/j.jare.2021.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jare.2021.11.013</ArticleId><ArticleId IdType="pmc">PMC8619886</ArticleId><ArticleId IdType="pubmed">36100326</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow A.K., Malone L.A., Kokorelis C., Petracek L.S., Eastin E.F., Lobner K.L., Neuendorff L., Rowe P.C. Long-term COVID-19 sequelae in adolescents: The overlap with orthostatic intolerance and ME/CFS. Curr. Ped. Rep. 2022;10:31&#x2013;44. doi: 10.1007/s40124-022-00261-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40124-022-00261-4</ArticleId><ArticleId IdType="pmc">PMC8906524</ArticleId><ArticleId IdType="pubmed">35287333</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y., Balshaw D.M., Kwok R.K., Thompson C.L., Collman G.W., Birnbaum L.S. The exposome: Embracing the complexity for discovery in environmental health. Environ. Health. Perspect. 2016;124:A137&#x2013;A140. doi: 10.1289/EHP412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/EHP412</ArticleId><ArticleId IdType="pmc">PMC4977033</ArticleId><ArticleId IdType="pubmed">27479988</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamdy A., Leonardi A. Superantigens and SARS-CoV-2. Pathogens. 2022;11:390. doi: 10.3390/pathogens11040390.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11040390</ArticleId><ArticleId IdType="pmc">PMC9026686</ArticleId><ArticleId IdType="pubmed">35456065</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M.H., Zhang S., Porrit R.A., Rivas M.N., Pschold L., Willscher E., Binder M., Arditi M., Bahar I. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Prot. Nat. Acad. Sci. USA. 2020;117:25254&#x2013;25262. doi: 10.1073/pnas.2010722117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2010722117</ArticleId><ArticleId IdType="pmc">PMC7568239</ArticleId><ArticleId IdType="pubmed">32989130</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaglioni V., Soriano E.R. Are superantigens the cause of cytokine storm and viral sepsis in severe COVID-19? Observations and hypothesis. Scand. J. Immunol. 2020;92:e12944. doi: 10.1111/sji.12944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12944</ArticleId><ArticleId IdType="pmc">PMC7404497</ArticleId><ArticleId IdType="pubmed">32697367</ArticleId></ArticleIdList></Reference><Reference><Citation>Gammazza A.M., L&#xe9;gar&#xe9; S., Lo Bosco G., Fucarino A., Angileri F., de Macario E.C., Macario A.J.L., Cappello F. Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: Possible role of molecular mimicry in COVID-19. Cell Stress Chaperones. 2020;25:737&#x2013;741. doi: 10.1007/s12192-020-01148-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-020-01148-3</ArticleId><ArticleId IdType="pmc">PMC7402394</ArticleId><ArticleId IdType="pubmed">32754823</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubkowska A., Pluta W., Stronska A., Lalko A. Role of heat shock proteins (Hsp70 and Hsp90) in viral infection. Int. J. Mol. Sci. 2021;22:9366. doi: 10.3390/ijms22179366.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22179366</ArticleId><ArticleId IdType="pmc">PMC8430838</ArticleId><ArticleId IdType="pubmed">34502274</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanneau D., Brunet M., Frisan E., Solary E., Fontenay M., Garrido C. Heat shock proteins: Essential proteins for apoptosis regulation: Apoptosis Review Series. J. Cell. Mol. Med. 2008;12:743&#x2013;761. doi: 10.1111/j.1582-4934.2008.00273.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00273.x</ArticleId><ArticleId IdType="pmc">PMC4401125</ArticleId><ArticleId IdType="pubmed">18266962</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard F.H.N., Kwan A., Winder N., Mughal A., Collado-Rojas C., Muthana M. Understanding immune response to viruses&#x2014;Do underlying Th1/Th2 cell biases predict outcome? Viruses. 2022;14:1493. doi: 10.3390/v14071493.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14071493</ArticleId><ArticleId IdType="pmc">PMC9324514</ArticleId><ArticleId IdType="pubmed">35891472</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagler C.R. Modern World Influences on the Microbiome and Their Consequences for Immune-Mediated Disease. J. Immunol. 2021;207:1695&#x2013;1696. doi: 10.4049/jimmunol.2190016.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2190016</ArticleId><ArticleId IdType="pubmed">34544809</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaser M. The theory of disappearing microbiota and the epidemics of chronic diseases. Nat. Rev. Immunol. 2017;17:461&#x2013;463. doi: 10.1038/nri.2017.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.77</ArticleId><ArticleId IdType="pubmed">28749457</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M.F., Wang G. Environmental agents, oxidative stress and autoimmunity. Curr. Opin. Toxicol. 2017;7:22&#x2013;27. doi: 10.1016/j.cotox.2017.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cotox.2017.10.012</ArticleId><ArticleId IdType="pmc">PMC5844495</ArticleId><ArticleId IdType="pubmed">29532040</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehner C., Fine R., Kriegel M. The microbiome in systemic autoimmune disease: Mechanistic insights from recent studies. Curr. Opin. Rheumatol. 2019;31:201&#x2013;207. doi: 10.1097/BOR.0000000000000574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000574</ArticleId><ArticleId IdType="pmc">PMC6408954</ArticleId><ArticleId IdType="pubmed">30624285</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca F., Shoenfeld Y. The microbiome in autoimmune diseases. Clin. Exp. Immunol. 2018;195:74&#x2013;85. doi: 10.1111/cei.13158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13158</ArticleId><ArticleId IdType="pmc">PMC6300652</ArticleId><ArticleId IdType="pubmed">29920643</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Selmi C., Tang R., Gershwin M.E., Ma X. The microbiome and autoimmunity: A paradigm from the gut&#x2013;liver axis. Cell. Mol. Immunol. 2018;15:595&#x2013;609. doi: 10.1038/cmi.2018.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2018.7</ArticleId><ArticleId IdType="pmc">PMC6079090</ArticleId><ArticleId IdType="pubmed">29706647</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., Mahroum N., Bogdanos D.P., Shoenfeld Y. COVID-19 as an infectome paradigm of autoimmunity. J. Allergy Clin. Immunol. 2022;149:63&#x2013;64. doi: 10.1016/j.jaci.2021.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.11.009</ArticleId><ArticleId IdType="pmc">PMC8610602</ArticleId><ArticleId IdType="pubmed">34826507</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Wang H., Sun Y., Ren Z., Zhu W., Li A., Cui G. Potential associations between microbiome and COVID-19. Front. Med. 2021;8:785496. doi: 10.3389/fmed.2021.785496.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.785496</ArticleId><ArticleId IdType="pmc">PMC8727742</ArticleId><ArticleId IdType="pubmed">35004750</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh Y.K. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70:698&#x2013;706. doi: 10.1136/gutjnl-2020-323020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323020</ArticleId><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinold J., Farahpour F., Schoerding A.-K., Fehring C., Dolff S., Konik M., Korth J., van Baal L., Buer J., Witzke O., et al. The fungal gut microbiome exhibits reduced diversity and increased relative abundance of Ascomycota in severe COVID illness and distinct interconnected communities in SARS-CoV-2 positive patients. Front. Cell. Infect. Microbiol. 2022;12:848650. doi: 10.3389/fcimb.2022.848650.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.848650</ArticleId><ArticleId IdType="pmc">PMC9062042</ArticleId><ArticleId IdType="pubmed">35521219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Zhan H., Zhang F., Liu Q., Tso E.Y.K., Lui G.C.Y., Chen N., Li A., Lu W., Chan F.K.L., et al. Alterations in fecal fungal microbiome of patients with covid-19 during time of hospitalization until discharge. Gastroenterology. 2020;159:1302&#x2013;1310. doi: 10.1053/j.gastro.2020.06.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.06.048</ArticleId><ArticleId IdType="pmc">PMC7318920</ArticleId><ArticleId IdType="pubmed">32598884</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Mak J.W.Y., Su Q., Yeoh Y.K., Lui G.C.Y., Ng S.S.S., Zhang F., Li A.Y.L., Lu W., Hui D.S.C., et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71:544&#x2013;552. doi: 10.1136/gutjnl-2021-325989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Wan Y., Zuo T., Yeoh Y.K., Liu Q., Zhang L., Zhan H., Lu W., Xu W., Lui G.C.Y., et al. Prolonged impairment of short-chain fatty acid and l-isoleucine biosynthesis in gut microbiome in patients with COVID-19. Gastroenterology. 2022;162:548&#x2013;561. doi: 10.1053/j.gastro.2021.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.10.013</ArticleId><ArticleId IdType="pmc">PMC8529231</ArticleId><ArticleId IdType="pubmed">34687739</ArticleId></ArticleIdList></Reference><Reference><Citation>Venzon M., Cadwell K. COVID-19 and the forgotten organ: Prolonged changes to the metabolic ouptut of the gut microbiome. Gastroenterology. 2022;162:394&#x2013;396. doi: 10.1053/j.gastro.2021.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.11.017</ArticleId><ArticleId IdType="pmc">PMC8596650</ArticleId><ArticleId IdType="pubmed">34800482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Liu Q., Zhang F., Lui G.C.-Y., Tso E.Y., Yeoh Y.K., Chen Z., Boon S.S., Chan F.K., Chan P.K., et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021;70:276&#x2013;284. doi: 10.1136/gutjnl-2020-322294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322294</ArticleId><ArticleId IdType="pmc">PMC7385744</ArticleId><ArticleId IdType="pubmed">32690600</ArticleId></ArticleIdList></Reference><Reference><Citation>Hejrati A., Rafiei A., Soltanshahi M., Hosseinzadeh S., DAbiri M., Taghadosi M., Taghiloo S., Bashash D., Khorsidi F., Zafari P. Innate immune response in systemic autoimmune diseases: A potential target of therapy. Inflammopharmacology. 2020;28:1421&#x2013;1438. doi: 10.1007/s10787-020-00762-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-020-00762-y</ArticleId><ArticleId IdType="pubmed">33006718</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordin P., Casari G., Townsend L., O&#x2019;Farrelly C., Tancevski I., L&#xf6;ffler-Ragg J., Mogensen T.H., Casanova J.L., COVID Human Genetic Effort Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat. Med. 2022;28:879&#x2013;889. doi: 10.1038/s41591-022-01766-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01766-7</ArticleId><ArticleId IdType="pubmed">35383311</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin. Immunol. 2020;217:108480. doi: 10.1016/j.clim.2020.108480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108480</ArticleId><ArticleId IdType="pmc">PMC7246018</ArticleId><ArticleId IdType="pubmed">32461193</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Vojdani E., Melgar A.L., Redd J. Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens. Front. Immunol. 2022;13:1003094. doi: 10.3389/fimmu.2022.1003094.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1003094</ArticleId><ArticleId IdType="pmc">PMC9537454</ArticleId><ArticleId IdType="pubmed">36211404</ArticleId></ArticleIdList></Reference><Reference><Citation>Churilov L.P., Normatov M.G., Utekhin V.J. Molecular mimicry between SARS-CoV-2 and human endocrinocytes: A prerequisite of post-COVID-19 endocrine autoimmunity? Pathophysiology. 2022;29:486&#x2013;494. doi: 10.3390/pathophysiology29030039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathophysiology29030039</ArticleId><ArticleId IdType="pmc">PMC9504401</ArticleId><ArticleId IdType="pubmed">36136066</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormiston C.K., Swiatkiewicz I., Taub P.R. Postural orthostatic syndrome as a sequela of COVID-19. Heart Rhythm. 2022;19:1880&#x2013;1889. doi: 10.1016/j.hrthm.2022.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2022.07.014</ArticleId><ArticleId IdType="pmc">PMC9287587</ArticleId><ArticleId IdType="pubmed">35853576</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Marques O., Halpert G., Schimke L.F., Ostrinski Y., Vojdani A., Baiocchi G.C., Freire P.P., Filgueiras I.S., Zyskind I., Lattin M.T., et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat. Commun. 2022;13:1220. doi: 10.1038/s41467-022-28905-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28905-5</ArticleId><ArticleId IdType="pmc">PMC8907309</ArticleId><ArticleId IdType="pubmed">35264564</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancho-Shimizu V., Brodin P., Cobat A., Biggs C.M., Toubiana J., Lucas C.L., Henrickson S.E., Belot A., MIS-C@CHGE. Tangye S.G. SARS-CoV-2&#x2013;related MIS-C: A key to the viral and genetic causes of Kawasaki disease? J. Exp. Med. 2021;218:e20210446. doi: 10.1084/jem.20210446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20210446</ArticleId><ArticleId IdType="pmc">PMC8080850</ArticleId><ArticleId IdType="pubmed">33904890</ArticleId></ArticleIdList></Reference><Reference><Citation>Consiglio C.R., Cotugno N., Sardh F., Pou C., Amodio D., Rodriguez L., Tan Z., Zicari S., Ruggiero A., Pascucci G.R., et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020;183:968&#x2013;981. doi: 10.1016/j.cell.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7474869</ArticleId><ArticleId IdType="pubmed">32966765</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli L., Motta F., De Santis M., Ansari A.A., Gershwin M.E., Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19&#x2014;A systematic review of the literature. J. Autoimmun. 2021;117:102592. doi: 10.1016/j.jaut.2020.102592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102592</ArticleId><ArticleId IdType="pmc">PMC7833462</ArticleId><ArticleId IdType="pubmed">33401171</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez Y., Novelli L., Rojas M., De Santis M., Acosta-Ampudia Y., Monsalve D.M., Ramirez-Santana C., Cistanzo A., Ridgway W.M., Ansari A.A., et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J. Autoimmun. 2020;114:102506. doi: 10.1016/j.jaut.2020.102506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102506</ArticleId><ArticleId IdType="pmc">PMC7296326</ArticleId><ArticleId IdType="pubmed">32563547</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianini M., Ohana M., Nespola B., Zanframundo G., Geny B., Meyer A. Similarities between COVID-19 and anti-MDA5 syndrome: What can we learn for better care? Eur. Respir. J. 2020;56:2001618. doi: 10.1183/13993003.01618-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01618-2020</ArticleId><ArticleId IdType="pmc">PMC7338399</ArticleId><ArticleId IdType="pubmed">32631836</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Du G., Zhang G., Matucci-Cerinic M., Furst D.E. Similarities and differences between severe COVID-19 pneumonia and MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: A challenge for the future. Ann. Rheum. Dis. 2022;81:e192. doi: 10.1136/annrheumdis-2020-218594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218594</ArticleId><ArticleId IdType="pubmed">32759260</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., Ogishi M., Sabli I.K.D., Hodeib S., Korol C., et al. Inborn errors of type 1 IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570. doi: 10.1126/science.abd4570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4570</ArticleId><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.-H., Zhang Y., Dorgham K., Philippot Q., Rosain J., B&#xe9;ziat V., et al. Autoantibodies against type1 IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>De Stefano L., Rossi S., Montecucco C., Bugatti S. Transient monoarthritis and psoriatic skin lesions following COVID-19. Ann. Rheum. Dis. 2020;2020:218520. doi: 10.1136/annrheumdis-2020-218520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218520</ArticleId><ArticleId IdType="pubmed">32753423</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew I.Y., Mak T.M., Cui L., Vasoo S., Lim X.R. A case of reactive arthritis secondary to Coronavirus Disease 2019 infection. J. Clin. Rheumatol. 2020;26:233. doi: 10.1097/RHU.0000000000001560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000001560</ArticleId><ArticleId IdType="pmc">PMC7437408</ArticleId><ArticleId IdType="pubmed">32694352</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono K., Kishimoto M., Shimasaki T., Uchida H., Kurai D., Deshpande G.A., Komagata Y., Kaname S. Reactive arthritis after COVID-19 infection. R.M.D. Open. 2020;6:e001350. doi: 10.1136/rmdopen-2020-001350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001350</ArticleId><ArticleId IdType="pmc">PMC7722270</ArticleId><ArticleId IdType="pubmed">32763956</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli L., Motta F., Ceribelli A., Guidelli G.M., Luciano N., Isailovic N., Vecellio M., Caprioli M., Clementi N., Clementi M., et al. A case of psoriatic arthritis triggered by SARS-CoV-2 infection. Rheumatology. 2021;60:e21&#x2013;e23. doi: 10.1093/rheumatology/keaa691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa691</ArticleId><ArticleId IdType="pmc">PMC7717387</ArticleId><ArticleId IdType="pubmed">33206980</ArticleId></ArticleIdList></Reference><Reference><Citation>Talarico R., Stagnaro C., Ferro F., Carli L., Mosca M. Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection. Lancet Rheumatol. 2020;2:e518&#x2013;e519. doi: 10.1016/S2665-9913(20)30216-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30216-2</ArticleId><ArticleId IdType="pmc">PMC7357970</ArticleId><ArticleId IdType="pubmed">32838313</ArticleId></ArticleIdList></Reference><Reference><Citation>Saricaoglu E.M., Hasanoglu I., Guner R. The first reactive arthritis case associated with COVID-19. J. Med. Virol. 2021;93:192&#x2013;193. doi: 10.1002/jmv.26296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26296</ArticleId><ArticleId IdType="pmc">PMC7405389</ArticleId><ArticleId IdType="pubmed">32652541</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokogawa N., Minematsu M., Katano H., Suzuki T. Case of acute arthritis following SARS-CoV-2 infection. Ann. Rheum. Dis. 2021;80:e101. doi: 10.1136/annrheumdis-2020-218281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218281</ArticleId><ArticleId IdType="pubmed">32591356</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Estes S.K., Ali R.A., Gandhi A.A., Yalavarthi S., Shi H., Sule G., Gockma K., Madison J.A., Zuo M., et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 2020;12:eabd3876. doi: 10.1126/scitranslmed.abd3876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H., Zuo Y., Navaz S., Harbaugh A., Hoy C.K., Gandhi A.A., Sule G., Yalavarthi S., Gockman K., Madison J.A., et al. Endothelial cell-activating antibodies in COVID-19. medRxiv. 2022 doi: 10.1002/art.42094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42094</ArticleId><ArticleId IdType="pmc">PMC9082472</ArticleId><ArticleId IdType="pubmed">35174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Ramos A.E., Martin-Nares E., Hern&#xe1;ndez-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. 2021;10:3592. doi: 10.3390/cells10123592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123592</ArticleId><ArticleId IdType="pmc">PMC8700122</ArticleId><ArticleId IdType="pubmed">34944099</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseini P., Fallahi M.S., Erabi G., Pakdin M., Zarezadeh S.M., Faridzadeh A., Entezari S., Ansari A., Poudineh M., Deravi N. Multisystem inflammatory syndrome and autoimmune disease following COVID-19: Molecular mechanisms and therapeutic opportunities. Front. Mol. Biosci. 2022;9:804109. doi: 10.3389/fmolb.2022.804109.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.804109</ArticleId><ArticleId IdType="pmc">PMC9046575</ArticleId><ArticleId IdType="pubmed">35495619</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpert G., Shoenfeld Y. SARS-CoV-2, the Autoimmune virus. Autoimmun. Rev. 2020;19:102695. doi: 10.1016/j.autrev.2020.102695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102695</ArticleId><ArticleId IdType="pmc">PMC7598743</ArticleId><ArticleId IdType="pubmed">33130000</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., Muller S., Kanduc D., David P., Halpert G., Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 2021;20:102792. doi: 10.1016/j.autrev.2021.102792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmune Res. 2020;19:102538. doi: 10.1016/j.autrev.2020.102538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102538</ArticleId><ArticleId IdType="pmc">PMC7131471</ArticleId><ArticleId IdType="pubmed">32268212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J. Transl. Autoimmun. 2020;3:100051. doi: 10.1016/j.jtauto.2020.100051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2020.100051</ArticleId><ArticleId IdType="pmc">PMC7142689</ArticleId><ArticleId IdType="pubmed">32292901</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K., Antoniadou A., Antonakos N., Damorakin G., Gkavogianni T., Adami M.-E., Katsaounou P., et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27:992&#x2013;1000.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Vojdani E., Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: Implications for autoimmune diseases. Front. Immunol. 2021;11:617089. doi: 10.3389/fimmu.2020.617089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.617089</ArticleId><ArticleId IdType="pmc">PMC7873987</ArticleId><ArticleId IdType="pubmed">33584709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanduc D., Shoenfeld Y. On the molecular determinants of the SARS-CoV-2 attack. Clin. Immunol. 2020;215:108426. doi: 10.1016/j.clim.2020.108426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108426</ArticleId><ArticleId IdType="pmc">PMC7165084</ArticleId><ArticleId IdType="pubmed">32311462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanduc D., Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: Implications for the vaccine. Immunol. Res. 2020;68:310&#x2013;313. doi: 10.1007/s12026-020-09152-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-020-09152-6</ArticleId><ArticleId IdType="pmc">PMC7499017</ArticleId><ArticleId IdType="pubmed">32946016</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker R.C. COVID-19-associated coagulopathy. J. Thromb. Thrombolysis. 2020;50:54&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7225095</ArticleId><ArticleId IdType="pubmed">32415579</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Xiao M., Zhang S., Xia P., Cao W., Jiang W., Chen H., Ding X., Zhao H., Zhang H., et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N. Engl. J. Med. 2020;382:e38. doi: 10.1056/NEJMc2007575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2007575</ArticleId><ArticleId IdType="pmc">PMC7161262</ArticleId><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Sawalha A.H., Lu Q. COVID-19 and autoimmune diseases. Curr. Opin. Rheumatol. 2020;33:155&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7880581</ArticleId><ArticleId IdType="pubmed">33332890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenfeld M., Tincani A., Andreoli L., Cattalini M., Greenbaum A., Kanduc D., Alijotas-Reig J., Zinserling V., Semenova N., Amital H., et al. COVID-19 and autoimmunity. Autoimmun. Rev. 2020;19:102597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289100</ArticleId><ArticleId IdType="pubmed">32535093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryabkova V.A., Churilov L.P., Shoenfeld Y. Influenza infection, SARS, MERS and COVID-19: Cytokine storm&#x2014;The common denominator and the lessons to be learned. Clin. Immunol. 2020;223:108652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832378</ArticleId><ArticleId IdType="pubmed">33333256</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkova A., Kudlay D., Kudryavtsev I., Starshinova A., Yablonskiy P., Shoenfeld Y. Immunogenetic predictors of severe COVID-19. Vaccines. 2021;9:211. doi: 10.3390/vaccines9030211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030211</ArticleId><ArticleId IdType="pmc">PMC8001669</ArticleId><ArticleId IdType="pubmed">33802310</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahroum N., Alghory A., Kiyak Z., Alwani A., Seida R., Alrais M., Shoenfeld Y. Ferritin&#x2014;From iron, through inflammation and autoimmunity, to COVID-19. J. Autoimmun. 2021;126:102778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8647584</ArticleId><ArticleId IdType="pubmed">34883281</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A. Molecular and immunological evidence for SARS-CoV-2 being the autoimmune virus; Proceedings of the Abstract, Oral Presentation, 13th International Congress on Autoimmunity; Athens, Greece. 10&#x2013;13 June 2022..</Citation></Reference><Reference><Citation>Nahmias A.J. Clinical aspects of infection with herpes simplex viruses 1 and 2. In: Nahmias A., Dowdle W.R., Shinazai R.F., editors. The Human Herpesviruses: An Interdisciplinary Perspective. Elsevier; Amsterdam, The Netherlands: 1981.</Citation></Reference><Reference><Citation>Virtanen J.O., Jacobson S. Viruses and multiple sclerosis. C.N.S. Neurol. Disord.-Drug Targets. 2012;11:528&#x2013;544. doi: 10.2174/187152712801661220.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152712801661220</ArticleId><ArticleId IdType="pmc">PMC4758194</ArticleId><ArticleId IdType="pubmed">22583435</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg A.H., Duus K., Houen G. Epstein-Barr virus and systemic lupus erythematosus. Clin. Dev. Immunol. 2012;2012:370516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3395176</ArticleId><ArticleId IdType="pubmed">22811739</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg A.H., Duus K., Houen G. Epstein-Barr virus in systemic autoimmune diseases. Clin. Dev. Immunol. 2013;2013:535738. doi: 10.1155/2013/535738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/535738</ArticleId><ArticleId IdType="pmc">PMC3766599</ArticleId><ArticleId IdType="pubmed">24062777</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S.-F., Wu H.-C., Tsai W.-C., Yen J.-H., Chiang W., You C.-Y., Lu S.-N., Chiang L.-C., Chen C.-J. Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. Med. Microbiol. Immunol. 2004;194:115&#x2013;120. doi: 10.1007/s00430-004-0230-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-004-0230-5</ArticleId><ArticleId IdType="pubmed">15378356</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon U.Y., Park S.J., Oh S.T., Kim W.-U., Park S.-H., Lee C.-H., Cho C.-S., Kim H.-Y., Lee W.-K. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res. Ther. 2004;6:R295&#x2013;R302. doi: 10.1186/ar1181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar1181</ArticleId><ArticleId IdType="pmc">PMC464871</ArticleId><ArticleId IdType="pubmed">15225364</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross A.J., Hochberg D., Rand W.M., Thorley-Lawson D.A. EBV and systemic lupus erythematosus: A new perspective. J. Immunol. 2005;174:6599&#x2013;6607. doi: 10.4049/jimmunol.174.11.6599.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.11.6599</ArticleId><ArticleId IdType="pubmed">15905498</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg A.H., Jorgensen J.M., M&#xfc;ller H., Nielsen C.T., Jacobsen S., Iversen L.V., Theander E., Nielsen L.P., Houen G., Duus K. Epstein-Barr virus early antigen diffuse (EBV-EA/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients. Scand. J. Rheumatol. 2012;41:280&#x2013;289. doi: 10.3109/03009742.2012.665944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2012.665944</ArticleId><ArticleId IdType="pubmed">22646970</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole B.D., Scofield R.H., Harley J.B., James J.A. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity. 2006;39:63&#x2013;70. doi: 10.1080/08916930500484849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930500484849</ArticleId><ArticleId IdType="pubmed">16455583</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwakiri D., Zhou L., Samanta M., Matsumoto M., Ebihara T., Seya T., Imai S., Fujieda M., Kawa K., Takada K. Epstein-Barr-virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3. J. Exp. Med. 2009;206:2091&#x2013;2099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757889</ArticleId><ArticleId IdType="pubmed">19720839</ArticleId></ArticleIdList></Reference><Reference><Citation>Jog N.R. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Ann. Rheum. Dis. 2019;78:1235&#x2013;1241. doi: 10.1136/annrheumdis-2019-215361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215361</ArticleId><ArticleId IdType="pmc">PMC6692217</ArticleId><ArticleId IdType="pubmed">31217170</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.J. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: Case control studies. J. Rheumatol. 2005;32:44&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">15630723</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman K.M. Peptide mimics of a major lupus epitope of SmB/B&#x2032;. Ann. N. Y. Acad. Sci. 2003;987:215&#x2013;229. doi: 10.1111/j.1749-6632.2003.tb06051.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2003.tb06051.x</ArticleId><ArticleId IdType="pubmed">12727642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mclain M.T. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum. 2006;54:360&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">16385527</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole B.D. Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. J Autoimmun. 2008;31:362371. doi: 10.1016/j.jaut.2008.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2008.08.007</ArticleId><ArticleId IdType="pmc">PMC2852321</ArticleId><ArticleId IdType="pubmed">18849143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandman-Goddard G. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann. N. Y. Acad. Sci. 2009;1173:658&#x2013;663. doi: 10.1111/j.1749-6632.2009.04754.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.04754.x</ArticleId><ArticleId IdType="pubmed">19758212</ArticleId></ArticleIdList></Reference><Reference><Citation>Esen B.A. Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: A controlled study. Rheumatol. Int. 2012;32:79&#x2013;83. doi: 10.1007/s00296-010-1573-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-010-1573-4</ArticleId><ArticleId IdType="pubmed">20661740</ArticleId></ArticleIdList></Reference><Reference><Citation>Vista E.S. Strong viral associations with SLE among Filipinos. Lupus Sci. Med. 2017;4:e000214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5704743</ArticleId><ArticleId IdType="pubmed">29214036</ArticleId></ArticleIdList></Reference><Reference><Citation>Morissette G., Flamand L. Herpesviruses and chromosomal integration. J. Virol. 2010;84:12100&#x2013;12109. doi: 10.1128/JVI.01169-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01169-10</ArticleId><ArticleId IdType="pmc">PMC2976420</ArticleId><ArticleId IdType="pubmed">20844040</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Lafuente R., Fern&#xe1;ndez-Guti&#xe9;rrez B., de Miguel S., Jover J.A., Rollin R., Loza E., Clemente D., Lamas J.R. Potential relationship between herpes viruses and rheumatoid arthritis: Analysis with qualitative real time polymerase chain reaction. Ann. Rheum. Dis. 2005;64:1357&#x2013;1359. doi: 10.1136/ard.2004.033514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.033514</ArticleId><ArticleId IdType="pmc">PMC1755640</ArticleId><ArticleId IdType="pubmed">16100341</ArticleId></ArticleIdList></Reference><Reference><Citation>Krueger G.R.F., Sander C., Hoffmann A., Barth A., Koch B., Braun M. Isolation of human herpesvirus-6 (HHV-6) from patients with collagen vascular diseases. In Vivo. 1991;5:217&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">1654147</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman A., Kirn E., Kuerten A., Sander C., Krueger G.R.F., Ablashi D.V. Active human herpesvirus-6 (HHV-6) infection associated with Kikuchi-Fujimoto disease and systemic lupus erythematosus (SLE) In Vivo. 1991;5:265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">1654149</ArticleId></ArticleIdList></Reference><Reference><Citation>Broccolo F., Drago F., Paolino S., Cassina G., Gatto F., Fusetti L., Matteoli B., Zaccaria E., Parodi A., Lusso P., et al. Reactivation of human herpesvirus 6 (HHV-6) infection in patients with connective tissue diseases. J. Clin. Virol. 2009;46:43&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">19515610</ArticleId></ArticleIdList></Reference><Reference><Citation>Broccolo F., Drago F., Cassina G., Fava A., Fusetti L., Matteoli B., Ceccherini-Nelli L., Sabbadini M.G., Lusso P., Parodi A., et al. Selective reactivation of human herpesvirus 6 in patients with autoimmune connective tissue diseases. J. Med. Virol. 2013;85:1925&#x2013;1934.</Citation><ArticleIdList><ArticleId IdType="pubmed">23983182</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranger-Rogez S., Vidal E., Liozon F., Denis F. Primary Sj&#xf6;gren&#x2019;s syndrome and antibodies to human herpesvirus type 6. Clin. Infect. Dis. 1994;19:1159&#x2013;1160. doi: 10.1093/clinids/19.6.1159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/19.6.1159</ArticleId><ArticleId IdType="pubmed">7888554</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli E., Soffritti I., D&#x2019;Accolti M., Bortolotti D., Sighinolfi G., Giuggioli D., Ferri C. HHV-6A infection and systemic sclerosis: Clues of a possible association. Microorganisms. 2020;8:39. doi: 10.3390/microorganisms8010039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8010039</ArticleId><ArticleId IdType="pmc">PMC7022325</ArticleId><ArticleId IdType="pubmed">31878218</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli E., Zatelli M.C., Rizzo R., Benedetti S., Martorelli D., Trasforini G., Cassai E., degli Uberti E.C., Di Luca D., Dolcetti R. Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto&#x2019;s thyroiditis. PLoS Pathog. 2012;8:100295</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464215</ArticleId><ArticleId IdType="pubmed">23055929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultanova A., Cistjakovs M., Gravelsina S., Chapenko S., Roga S., Cunskis E., Nore-Krukle Z., Groma V., Ventina I., Murovska M. Association of active human herpesvirus 6 (HHV-6) infection with autoimmune thyroid gland diseases. Clin. Microbiol. Infect. 2017;23:e1&#x2013;e50. doi: 10.1016/j.cmi.2016.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2016.09.023</ArticleId><ArticleId IdType="pubmed">27693656</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldan S.S., Berti R., Salem N., Secchiero P., Flamand L., Calabresi P.A., Brennan M.B., Maloni H.W., McFarland H.F., Lin H.C., et al. Association of human herpesvirus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nature Med. 1997;3:1394&#x2013;1397. doi: 10.1038/nm1297-1394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1297-1394</ArticleId><ArticleId IdType="pubmed">9396611</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillet A.M., Lozeron P., Augt H., Lyon-Caen O., Liblau R. HHV-6 and multiple sclerosis. Nat. Med. 1998;4:537. doi: 10.1038/nm0598-537a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0598-537a</ArticleId><ArticleId IdType="pubmed">9585208</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates A.R., Bell J. HHV-6 and multiple sclerosis. Nat. Med. 1998;4:537&#x2013;538. doi: 10.1038/nm0598-537b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0598-537b</ArticleId><ArticleId IdType="pubmed">9585209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablashi D.V., Lapps W., Kaplan M., Whitman J.E., Richert J.R., Pearson G.R. Human herpesvirus-6 (HHV-6) in multiple sclerosis: A preliminary report. Mult. Scler. 1998;4:490&#x2013;496. doi: 10.1177/135245859800400606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135245859800400606</ArticleId><ArticleId IdType="pubmed">9987758</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman J.E., Lyons M.J., Cu G., Ablashi D.V., Whitman J.E., Edgar M., Koskiniemi M., Vaheri A., Zabriskie J.B. The association of the human herpesvirus-6 and MS. Mult. Scler. 1999;5:355&#x2013;362. doi: 10.1177/135245859900500509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135245859900500509</ArticleId><ArticleId IdType="pubmed">10516780</ArticleId></ArticleIdList></Reference><Reference><Citation>Voumvourakis K.I., Kitsos D.K., Tsiodras S., Petrikkos G., Stamboulis E. Human herpesvirus 6 infection as a trigger of multiple sclerosis. Mayo Clin. Proc. 2010;11:1023&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966366</ArticleId><ArticleId IdType="pubmed">20926836</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhyani N., Berti R., Brennan M.B., Soldan S.S., Eaton J.M., McFarland H.F., Jacobson S. Tissue distribution and variant characterization of human herpesvirus (HHV-6) increased prevalence of HHV-6A in patients with multiple sclerosis. J. Infect. Dis. 2000;182:1321&#x2013;1325. doi: 10.1086/315893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/315893</ArticleId><ArticleId IdType="pubmed">11023456</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders V.J., Felisan S., Waddell A., Tourtellotte W.W. Detection of Herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J. Neurovirol. 1996;2:249&#x2013;258. doi: 10.3109/13550289609146888.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13550289609146888</ArticleId><ArticleId IdType="pubmed">8799216</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.-S., Lee K.-S., Park J.-H., Kim M.-Y., Shin W.-S. Detection of human herpesvirus 6 variant A in peripheral blood mononuclear cells from multiple sclerosis patients. Eur. Neurol. 2000;43:170&#x2013;173. doi: 10.1159/000008158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000008158</ArticleId><ArticleId IdType="pubmed">10765058</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapenko S., Millers A., Nora Z., Logina I., Kukaine R., Murovska M. Correlation beteeen HHV-6 reactivation and multiple sclerosis disease activity. J. Med. Virol. 2003;69:111&#x2013;117. doi: 10.1002/jmv.10258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.10258</ArticleId><ArticleId IdType="pubmed">12436486</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotola A., Merlotti I., Caniatti L., Caselli E., Granieri E., Tola M.R., Di Luca D., Cassai E. Human herpesvirus 6 infects the central nervous system of multiple sclerosis patients in the early stages of the disease. Mult. Scler. 2004;10:348&#x2013;354. doi: 10.1191/1352458504ms1045oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/1352458504ms1045oa</ArticleId><ArticleId IdType="pubmed">15327028</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman A.D., Mock D.J., Powers J.M., Baker J.V., Blumberg B.M. Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions. J. Infect. Dis. 2003;187:1365&#x2013;1376. doi: 10.1086/368172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/368172</ArticleId><ArticleId IdType="pubmed">12717617</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilborn F., Schmidt C.A., Brinckmann V., Jendroska K., Oettle H., Siegert W. A potential role for human herpesvirus type 6 in nervous system disease. J. Neuroimmunol. 1994;49:213&#x2013;214. doi: 10.1016/0165-5728(94)90198-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(94)90198-8</ArticleId><ArticleId IdType="pubmed">8294559</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Lafuente R., De Las Heras V., Bartolome M., Picazo J.J., Arroyo R. Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. Arch. Neurol. 2004;61:1523&#x2013;1527. doi: 10.1001/archneur.61.10.1523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.61.10.1523</ArticleId><ArticleId IdType="pubmed">15477505</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson S., Taylor B., Dwyer D.E., Taylor J., Blizzard L., Ponsonby A.-L., Pittas F., Dwyer T., van der Mei I. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. Mult. Scler. 2012;18:799&#x2013;806. doi: 10.1177/1352458511428081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458511428081</ArticleId><ArticleId IdType="pubmed">22084489</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-P&#xe9;rez S., Dominguez-Mozo M., Garc&#xed;a-Martinez M.A., Garcia-Frontini M.C., Villarubia N., Costa-Frossard L., Villar L.M., Arroyo R., Alvarez-Lafuente R. Anti-human herpesvirus 6 A/B antibodies titers correlate with multiple sclerosis-associated retrovirus envelope expression. Front. Immunol. 2021;12:798003. doi: 10.3389/fimmu.2021.798003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.798003</ArticleId><ArticleId IdType="pmc">PMC8666430</ArticleId><ArticleId IdType="pubmed">34912348</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Mozo M.I., Perez-Perez S., Villarubia N., Costa-Frossard L., Fernandez-Velasco J.I., Ortega-Madue&#xf1;o I., Garcia-Martinez M.A., Garcia-Calvo E., Estevez H., Garcia J.L.L., et al. Herpesvirus antibodies, vitamin D and short-chain fatty acids: Their correlation with cell subsets in multiple sclerosis patients and healthy controls. Cells. 2021;10:119. doi: 10.3390/cells10010119.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10010119</ArticleId><ArticleId IdType="pmc">PMC7826528</ArticleId><ArticleId IdType="pubmed">33435197</ArticleId></ArticleIdList></Reference><Reference><Citation>Grima P., Chiavaroli R., Calabrese P., Tundo P. Severe hepatitis with autoimmune features following a HHV-6: A case report. Cases J. 2008;1:110. doi: 10.1186/1757-1626-1-110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1757-1626-1-110</ArticleId><ArticleId IdType="pmc">PMC2531091</ArticleId><ArticleId IdType="pubmed">18710564</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagasaki H., Kato M., Shimizu N., Shichino H., Chin M., Mugishima H. Autoimmune hemolytic anemia and autoimmune neutropenia in a child with erythroblastopenia of childhood (TEC) caused by human herpesvirus-6 (HHV-6) Ann. Hematol. 2011;90:851. doi: 10.1007/s00277-010-1095-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-010-1095-x</ArticleId><ArticleId IdType="pubmed">20922523</ArticleId></ArticleIdList></Reference><Reference><Citation>Faierstein K., Shilo N., Levartovsky A., Raphael R., Givon A., Agmon-Levin N., Mayan H. Autoimmune neutropenia associated with HHV-6 virus infection: A case report. Front. Immunol. 2022;13:880016. doi: 10.3389/fimmu.2022.880016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.880016</ArticleId><ArticleId IdType="pmc">PMC9124847</ArticleId><ArticleId IdType="pubmed">35615353</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapenko S., Krumina A., Kozireva S., Nora Z., Sultanova A., Viksna L., Murovska M. Activation of human herpesviruses 6 and 7 in patients with chronic fatigue syndrome. J. Clin. Virol. 2006;37((Suppl. S1)):S47&#x2013;S51. doi: 10.1016/S1386-6532(06)70011-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1386-6532(06)70011-7</ArticleId><ArticleId IdType="pubmed">17276369</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapenko S., Krumina A., Logina I., Rasa S., Chistjakovs M., Sultanova A., Viksna L., Murovska M. Association of active human herpesvirus-6, -7 and parvovirus b19 infection with clinical outcomes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Adv. Virol. 2012;2012:205085. doi: 10.1155/2012/205085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/205085</ArticleId><ArticleId IdType="pmc">PMC3426163</ArticleId><ArticleId IdType="pubmed">22927850</ArticleId></ArticleIdList></Reference><Reference><Citation>Myhill S., Booth N.E., McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfuncrtion. Int. J. Clin. Exp. Med. 2009;2:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680051</ArticleId><ArticleId IdType="pubmed">19436827</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G., Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab. Brain Dis. 2014;29:19&#x2013;36. doi: 10.1007/s11011-013-9435-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-013-9435-x</ArticleId><ArticleId IdType="pubmed">24557875</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiner P., Harrer T., Scheibenbogen C., Lamer S., Schlosser A., Naviaux R.K., Prusty B.K. Human herpesvirus-6 reactivation, mitochondrial fragmentation, and the coordination of antiviral and metabolic phenotypes in myalgic encephalomyelitis/chronic fatigue syndrome. Immunohorizons. 2020;4:201&#x2013;215. doi: 10.4049/immunohorizons.2000006.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.2000006</ArticleId><ArticleId IdType="pubmed">32327453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lino K., Alves L.S., Raposo J.V., Medeiros T., Souza C.F., da Silva A.A., de Paula V.S., Almeida J.R. Presence and clinical impact of human herpesvirus-6 infection in patients with moderate to critical coronavirus disease-19. J. Med. Virol. 2022;94:1212&#x2013;1216. doi: 10.1002/jmv.27392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27392</ArticleId><ArticleId IdType="pmc">PMC8662171</ArticleId><ArticleId IdType="pubmed">34647632</ArticleId></ArticleIdList></Reference><Reference><Citation>Drago F., Ciccarese G., Rebora A., Parodi A. Human herpesvirus-6, -7, and Epstein-Barr virus reactivation inpityriasis roseaduring COVID-19. J. Med. Virol. 2020;93:1850&#x2013;1851. doi: 10.1002/jmv.26549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26549</ArticleId><ArticleId IdType="pmc">PMC7537064</ArticleId><ArticleId IdType="pubmed">32970319</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigley T.M., Yang L., Kang L.-I., Saenz J.B., Victorino F., Yokoyama W.M. Disruption of thymic central tolerance by infection with murine roseolovirus induces autoimmune gastritis. J. Exp. Med. 2022;219:e20211403. doi: 10.1084/jem.20211403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211403</ArticleId><ArticleId IdType="pmc">PMC8932538</ArticleId><ArticleId IdType="pubmed">35226043</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M., Rodriguez Y., Acosta-Ampudia Y., Monsalve D.M., Zhu C., Li Q.-Z., Ramirez-Santana C., Anaya J.-M. Autoimmunity is a hallmark of post-COVID syndrome. J. Transl. Med. 2022;20:129. doi: 10.1186/s12967-022-03328-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03328-4</ArticleId><ArticleId IdType="pmc">PMC8924736</ArticleId><ArticleId IdType="pubmed">35296346</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B., Howe A. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Derwand R., Scholz M., Zelenko V. COVID-19 outpatients: Early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azythromycin. A retrospective case series study. Int. J. Antimicrob. Agents. 2020;56:106214. doi: 10.1016/j.ijantimicag.2020.106214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106214</ArticleId><ArticleId IdType="pmc">PMC7587171</ArticleId><ArticleId IdType="pubmed">33122096</ArticleId></ArticleIdList></Reference><Reference><Citation>Formiga F.R., Leblanc R., Reboucas J.S., FariS L.P., De Oliveira R.N., Pena L. Ivermectin: An award-winning drug with expected antiviral activity against COVID-19. J. Control. Release. 2021;329:758&#x2013;761. doi: 10.1016/j.jconrel.2020.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.10.009</ArticleId><ArticleId IdType="pmc">PMC7539925</ArticleId><ArticleId IdType="pubmed">33038449</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazan S. Microbiome-based hypothesis on Ivermectin&#x2019;s mechanism in COVID-19: Ivermectin feeds Bifidobacteria to boost immunity. Front. Microbiol. 2022;13:952321. doi: 10.3389/fmicb.2022.952321.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.952321</ArticleId><ArticleId IdType="pmc">PMC9309549</ArticleId><ArticleId IdType="pubmed">35898916</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M., Schultz M.B., Sinclair D.A. NAD+ in COVID-19 and viral infections. Trends Immunol. 2022;43:283&#x2013;295. doi: 10.1016/j.it.2022.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.001</ArticleId><ArticleId IdType="pmc">PMC8831132</ArticleId><ArticleId IdType="pubmed">35221228</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoust L., Pilon G., Marette A. Perspective: Nutritional strategies targeting the gut microbiome to mitigate COVID-19 outcomes. Adv. Nutr. 2021;12:1074&#x2013;1086. doi: 10.1093/advances/nmab031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/advances/nmab031</ArticleId><ArticleId IdType="pmc">PMC8083677</ArticleId><ArticleId IdType="pubmed">33783468</ArticleId></ArticleIdList></Reference><Reference><Citation>Gang J., Wang H., Xue X., Zhang S. Microbiota and COVID-19: Long-term and complex influencing factors. Front. Microbiol. 2022;13:963488. doi: 10.3389/fmicb.2022.963488.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.963488</ArticleId><ArticleId IdType="pmc">PMC9417543</ArticleId><ArticleId IdType="pubmed">36033885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Zhang L., Wang Y., Dai T., Qin Z., Zhou F., Zhang L. Alterations in microbiota of patients with COVID-19: Potential and therapeutic interventions. Signal Transduct. Target. Ther. 2022;7:143. doi: 10.1038/s41392-022-00986-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00986-0</ArticleId><ArticleId IdType="pmc">PMC9052735</ArticleId><ArticleId IdType="pubmed">35487886</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda Y., Motooka D., Kawasaki T., Oki H., Noda Y., Adachi Y., Niitsu T., Okamoto S., Tanaka K., Fukushima K., et al. Longitudinal alterations of the gut mycobiota and microbiota on COVID-19 severity. BMC Infect. Dis. 2022;22:572. doi: 10.1186/s12879-022-07358-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07358-7</ArticleId><ArticleId IdType="pmc">PMC9233337</ArticleId><ArticleId IdType="pubmed">35751044</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Wu G., Zhao L., Wang W. Nutritional modulation of gut microbiota alleviates severe gastrointestinal symptoms in patients with post-acute COVID-19 syndrome. mBio. 2022;13:e0380121. doi: 10.1128/mbio.03801-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03801-21</ArticleId><ArticleId IdType="pmc">PMC9040862</ArticleId><ArticleId IdType="pubmed">35254129</ArticleId></ArticleIdList></Reference><Reference><Citation>Haran J.P., Zheng Y., Knobil K., Palma N.A., Lawrence J.F., Wingertzahn M.A. Targeting the microbiome with KB109 in outpatients with mild to moderate COVID-19 reduced medically attended acute care visits and improved symptoms in patients with comorbidities. medRxiv. 2021 doi: 10.1101/2021.03.26.21254422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.26.21254422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T., Perlot T., Rehman A., Trichereau J., Ishiguro H., Paolino M., Sigl V., Hanada T., Hanada R., Lipinski S., et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487:477&#x2013;481. doi: 10.1038/nature11228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11228</ArticleId><ArticleId IdType="pmc">PMC7095315</ArticleId><ArticleId IdType="pubmed">22837003</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A., Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221&#x2013;224. doi: 10.1038/s41586-020-2179-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2179-y</ArticleId><ArticleId IdType="pmc">PMC7328981</ArticleId><ArticleId IdType="pubmed">32225175</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers M.M., Beumer J., van der Vaart J., Knoops K., Puschhof J., Breugem T.I., Ravelli R.B.G., van Schayck J.P., Mykytyn A.Z., Duimel H.Q., et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369:50&#x2013;54. doi: 10.1126/science.abc1669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1669</ArticleId><ArticleId IdType="pmc">PMC7199907</ArticleId><ArticleId IdType="pubmed">32358202</ArticleId></ArticleIdList></Reference><Reference><Citation>Penninger J.M., Grant M.B., Sung J.J.Y. The role of angiotensin converting enzyme 2 in modulating gut microbiota, intestinal inflammation, and coronavirus infection. Gastroenterology. 2021;160:39&#x2013;46. doi: 10.1053/j.gastro.2020.07.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.07.067</ArticleId><ArticleId IdType="pmc">PMC7836226</ArticleId><ArticleId IdType="pubmed">33130103</ArticleId></ArticleIdList></Reference><Reference><Citation>Foolchand A., Mazaleni S., Ghazi T., Chuturgoon A.A. A review: Highlighting the links between epigenetics, COVID-19 infection, and vitamin D. Int. J. Mol. Sci. 2022;23:12292. doi: 10.3390/ijms232012292.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232012292</ArticleId><ArticleId IdType="pmc">PMC9603374</ArticleId><ArticleId IdType="pubmed">36293144</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannis F., Peukert K., Surace L., Michla M., Nikolka F., Fox M., Weiss P., Feuerborn C., Maier P., Schulz S., et al. Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19. Nature. 2022;609:801&#x2013;807. doi: 10.1038/s41586-022-05128-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05128-8</ArticleId><ArticleId IdType="pmc">PMC9428867</ArticleId><ArticleId IdType="pubmed">35901960</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Vargas J., Shapira T., Olmstead A.D., Villanueva I., Thompson C.A.H., Ennis S., Gao G., De Guzman J., Williams D.E., Wang M. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics. Antivir. Res. 2023;209:105484. doi: 10.1016/j.antiviral.2022.105484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105484</ArticleId><ArticleId IdType="pmc">PMC9729583</ArticleId><ArticleId IdType="pubmed">36503013</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B., Mohn K.G.-I., Brokstad K.A., Zhou F., Linchausen D.W., Hansen B.-A., Lartey S., Onyango T.B., Kuwelker K., Saeqvik M., et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 2021;27:1607&#x2013;1613. doi: 10.1038/s41591-021-01433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Zhang S., Wu Z., Shang Y., Dong X., Li G., Zhang L., Chen Y., Ye X., Du H., et al. Clinical outcomes of COVID-19 in Wuhan, China: A large cohort study. Ann. Intensive Care. 2020;10:99. doi: 10.1186/s13613-020-00706-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-020-00706-3</ArticleId><ArticleId IdType="pmc">PMC7393341</ArticleId><ArticleId IdType="pubmed">32737627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino Y., Katano H., Zou P., Hohman P., Marques A., Tyring S.K., Follmann D., Cohen J.I. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of DNA copies per B cell in healthy volunteers. J. Virol. 2009;83:11857&#x2013;11861. doi: 10.1128/JVI.01005-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01005-09</ArticleId><ArticleId IdType="pmc">PMC2772668</ArticleId><ArticleId IdType="pubmed">19740997</ArticleId></ArticleIdList></Reference><Reference><Citation>Verna D., Thompson J., Swaminathan S. Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function. Proc. Natl. Acad. Sci. USA. 2016;113:3609&#x2013;3614. doi: 10.1073/pnas.1523686113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1523686113</ArticleId><ArticleId IdType="pmc">PMC4822607</ArticleId><ArticleId IdType="pubmed">26976570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kottis K., Lechowicz K., Drozdzal S., Niedzwiedzka-Rystwej P., Wojdacz T.K., Grywalska E., Biernawska J., Wisniewska M., Parczewski M. COVID-19: The potential beneficial therapeutic effects of Spironolactone during SARS-CoV-2 infection. Pharmaceuticals. 2021;14:71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7830835</ArticleId><ArticleId IdType="pubmed">33477294</ArticleId></ArticleIdList></Reference><Reference><Citation>Mareev V.Y., Orlova Y.A., Plisyk A.G., Pavlikova E.P., Matskeplishvili S.T., Akopyan Z.A., Seredenina E.M., Potapenko A.V., Agapov M.A., Asratyan D.A., et al. Results of open-label non-randomized comparative clinical trial: BromhexIne and Spironolactone for CoronavirUs Infection requiring hospiTalization (BISCUIT) Kardologia. 2020;60:4&#x2013;15. doi: 10.18087/cardio.2020.11.n1440.</Citation><ArticleIdList><ArticleId IdType="doi">10.18087/cardio.2020.11.n1440</ArticleId><ArticleId IdType="pubmed">33487145</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnon K.H., Leist S.R., Okuda K., Dang H., Fritch E.J., Gully K.L., De la Cruz G., Evangelista M.D., Asakura T., Gilmore R.C., et al. SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Sci. Transl. Med. 2022;14:eabo5070. doi: 10.1126/scitranslmed.abo5070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abo5070</ArticleId><ArticleId IdType="pmc">PMC9273046</ArticleId><ArticleId IdType="pubmed">35857635</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Advancing Translational Sciences (NCATS)   NIH Begins Large Clinical Trial to Test Immune Modulators for Treatment of COVID-19. National Institutes of Health (NIH); Bethesda, MD, USA: 2020.  [(accessed on 19 September 2022)].  Available online:  https://www.nih.gov/news-events/news-releases/nih-begins-large-clinical-trial-test-immune-modulators-treatment-covid-19.</Citation></Reference><Reference><Citation>National Institutes of Health (NIH)   Immune Modulator Drugs Improved Survival for People Hospitalized with COVID-19. National Institutes of Health (NIH); Bethesda, MD, USA: 2022.  [(accessed on 19 September 2022)].  Available online:  https://www.nih.gov/news-events/news-releases/immune-modulator-drugs-improved-survival-people-hospitalized-covid-19.</Citation></Reference><Reference><Citation>Pinto M.D., Lambert N., Downs C.A., Abrahim H., Hughes T.D., Rahmani A.M., Burton C.W., Chakraborty R. Antihistamines for postacute sequelae of SARS-CoV-2 infection. J. Nurse Pract. 2022;18:335&#x2013;338. doi: 10.1016/j.nurpra.2021.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nurpra.2021.12.016</ArticleId><ArticleId IdType="pmc">PMC8820139</ArticleId><ArticleId IdType="pubmed">35153633</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P., Tahmasebi N., Gant V., Gupta R. Long COVID following mild SARS-CoV-2 infection: Characteristic T cell alterations and response to antihistamines. J. Investig. Med. 2021;70:61&#x2013;67. doi: 10.1136/jim-2021-002051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  Interim Guidance on Evaluating and Caring for Patients with Post-COVID Conditions.  [(accessed on 11 October 2022)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covidindex.html.</Citation></Reference><Reference><Citation>Herman E., Shih E., Cheng A. Long COVID: Rapid evidence review. Am. Fam. Physician. 2022;106:523&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">36379497</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera J.E., Niehaus W.N., Whiteson J., Azola A., Baratta J.M., Fleming T.K., Kim S.Y., Naqvi H., Sampsel S., Silver J.K., et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) Pm R. 2021;13:1027&#x2013;1043. doi: 10.1002/pmrj.12684. corrected in Pm R 2022, 14, 164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmrj.12684</ArticleId><ArticleId IdType="pmc">PMC8441628</ArticleId><ArticleId IdType="pubmed">34346558</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen L.R., Sami S., Vuong N., Pathela P., Weiss D., Morgenthau B.M., Henseler R.A., Daskalakis D.C., Atas J., Patel A., et al. Lack of antibodies to severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) in a large cohort of previously infected persons. Clin. Infect. Dis. 2021;73:e3066&#x2013;e3073. doi: 10.1093/cid/ciaa1685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1685</ArticleId><ArticleId IdType="pmc">PMC7665429</ArticleId><ArticleId IdType="pubmed">33147319</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M. Long COVID: A primer for family physicians. Am. Fam. Physician. 2020;102:716&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">33320511</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., Redfield S., Austin J.P., Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EclinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance H., Maslach A., Stoneman E., Harmes K., Ransom A., Seagly K., Furst W. Addressing post-COVID symptoms: A guide for primary care physicians. J. Am. Board Fam. Med. 2021;34:1229&#x2013;1242. doi: 10.3122/jabfm.2021.06.210254.</Citation><ArticleIdList><ArticleId IdType="doi">10.3122/jabfm.2021.06.210254</ArticleId><ArticleId IdType="pubmed">34772779</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine J.S., Ambrose A.F., Didehbani N., Fleming T.K., Glashan L., Longo M., Merlino A., Ng R., Nora G.J., Rolin S., et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cognitive symptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC) PM R. 2022;14:96&#x2013;111. doi: 10.1002/pmrj.12745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmrj.12745</ArticleId><ArticleId IdType="pubmed">34902226</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E., Ba D.M., Parsons N., Poudel G.R., Lekoubou A., Oh J.S., Ericson J.E., Ssentongo P., et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw. Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaylis N.B., Ritter A., Kelly S.A., Pourhassan N.Z., Tiwary M., Sacha J.B., Hansen S.G., Recknor C., Yang O.O. Reduced cell surface levels of C-C chemokine receptor 5 and immunosuppression in long coronavirus disease 2019 syndrome. Clin. Infect. Dis. 2022;75:1232&#x2013;1234. doi: 10.1093/cid/ciac226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac226</ArticleId><ArticleId IdType="pmc">PMC9383814</ArticleId><ArticleId IdType="pubmed">35452519</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil S., Gualano B., Ladeira de Araujo A., Nascimento de Oliveira G., Jr., Damiano R.F., Pinna F., Imamura M., Rocha V., Kallas E., Batistella L.R., et al. Post-acute sequelae of SARS-CoV-2 associates with physical inactivity in a cohort of COVID-19 survivors. Sci. Rep. 2023;13:215. doi: 10.1038/s41598-022-26888-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-26888-3</ArticleId><ArticleId IdType="pmc">PMC9813883</ArticleId><ArticleId IdType="pubmed">36604523</ArticleId></ArticleIdList></Reference><Reference><Citation>Scurati R., Papini N., Alberti G., Tringali C. The challenge of long COVID-19 management: From disease molecular hallmarks to the proposal of exercise as therapy. Int. J. Mol. Sci. 2022;23:12311. doi: 10.3390/ijms232012311.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232012311</ArticleId><ArticleId IdType="pmc">PMC9603679</ArticleId><ArticleId IdType="pubmed">36293160</ArticleId></ArticleIdList></Reference><Reference><Citation>Iddir M., Brito A., Dingeo G., Del Campo S.S.F., Samouda H., La Frano M.R., Bohn T. Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition: Considerations during the COVID-19 crisis. Nutrients. 2020;12:1562. doi: 10.3390/nu12061562.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12061562</ArticleId><ArticleId IdType="pmc">PMC7352291</ArticleId><ArticleId IdType="pubmed">32471251</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M., Lyle B.J., Madsen K.L., Sonnenburg J., Verbeke K., Wu G.D. Role for diet in normal gut barrier function: Developing guidance within the framework of food-labeling regulations. Am. J. Physiol. Gastrointest. Liver Physiol. 2019;317:G17&#x2013;G39. doi: 10.1152/ajpgi.00063.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00063.2019</ArticleId><ArticleId IdType="pmc">PMC6689735</ArticleId><ArticleId IdType="pubmed">31125257</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Xu Z., Mak J.W.Y., Chan F.K.L., Ng S.C. SIM01 as a novel microbiome replacement therapy for COVID-19: An open-label pilot study. J. Gastroenterol. Hepatol. 2021;36:272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115073</ArticleId><ArticleId IdType="pubmed">35170078</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;323:1824&#x2013;1836. doi: 10.1001/jama.2020.6019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6019</ArticleId><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoufaly A., Poglitsch M., Aberle J.H., Hoepler W., Seitz T., Traugott M., Grieb A., Pawelka E., Laferi H., Wenisch C. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir. Med. 2020;8:1154&#x2013;1158. doi: 10.1016/S2213-2600(20)30418-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30418-5</ArticleId><ArticleId IdType="pmc">PMC7515587</ArticleId><ArticleId IdType="pubmed">33131609</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A., Xu K., Du T., Zhu P., Liang Z., Liao S., Zhang J., Raizada M.K., Grant M.B., Li Q. Expression of human ACE2 in Lactobacillus and beneficial effects in diabetic retinopathy in mice. Mol. Ther. Methods Clin. Dev. 2019;14:161&#x2013;170. doi: 10.1016/j.omtm.2019.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2019.06.007</ArticleId><ArticleId IdType="pmc">PMC6661465</ArticleId><ArticleId IdType="pubmed">31380462</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilinski J., Winter K., Jasinski M., Szczes A., Bilinska N., Mullish B.H., Malecka-Panas E., Basak G.W. Rapid resolution of COVID-19 after faecal microbiota transplantation. Gut. 2022;71:230&#x2013;232. doi: 10.1136/gutjnl-2021-325010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325010</ArticleId><ArticleId IdType="pubmed">34230217</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianiro G., Mullish B.H., Kelly C.R., Kassam Z., Kujiper E.J., Ng S.C., Iqbal T.H., Allegretti J.R., Bibb&#xf3; S., Sokol H., et al. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut. 2020;69:1555&#x2013;1563. doi: 10.1136/gutjnl-2020-321829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321829</ArticleId><ArticleId IdType="pmc">PMC7456726</ArticleId><ArticleId IdType="pubmed">32620549</ArticleId></ArticleIdList></Reference><Reference><Citation>Laursen R.P., Hojsak I. Probiotics for respiratory tract infections in children attending day care centers&#x2014;A systematic review. Eur. J. Pediatr. 2018;177:979&#x2013;994. doi: 10.1007/s00431-018-3167-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-018-3167-1</ArticleId><ArticleId IdType="pubmed">29752587</ArticleId></ArticleIdList></Reference><Reference><Citation>De Filippis F., Pellegrini N., Vannini L., Jeffery I.B., La Storia A., Laghi L., Serrazenetti D.I., Di Cagno R., Ferrocino I., Lazzi C., et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut. 2016;65:1812&#x2013;1821. doi: 10.1136/gutjnl-2015-309957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-309957</ArticleId><ArticleId IdType="pubmed">26416813</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarado D.M., Son J., Thackray L.B., Diamond M.S., Ding S., Ciorba M.A. IBD Investigators Group at Washington University. Mesalamine reduces intestinal ACE2 expression without modifying SARS-CoV-2 infection or disease severity in mice. bioRxiv. 2021 bioRxiv:2021.07.23.453393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8690199</ArticleId><ArticleId IdType="pubmed">34849936</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudryavtsev I., Rubinstein A., Golovkin A., Kalinina O., Vasilyev K., Rudenko L., Isakova-Sivak I. Dysregulated immune responses in SARS-CoV-2-infected patients: A comprehensive overview. Viruses. 2022;14:1082. doi: 10.3390/v14051082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14051082</ArticleId><ArticleId IdType="pmc">PMC9147674</ArticleId><ArticleId IdType="pubmed">35632823</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkova A., Kudryavtsev I., Starshinova A., Kudlay D., Zinchenko Y., Glushkova A., Yablonskiy P., Shoenfeld Y. Post COVID-19 Syndrome in Patients with Asymptomatic/Mild Form. Pathogens. 2021;10:1408. doi: 10.3390/pathogens10111408.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10111408</ArticleId><ArticleId IdType="pmc">PMC8620929</ArticleId><ArticleId IdType="pubmed">34832564</ArticleId></ArticleIdList></Reference><Reference><Citation>Maglietta G., Diodati F., Puntoni M., Lazzarelli S., Marcomini B., Patrizi L., Caminiti C. Prognostic factors for post-COVID-19 syndrome: A systematic review and meta-analysis. J. Clin. Med. 2022;11:1541. doi: 10.3390/jcm11061541.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11061541</ArticleId><ArticleId IdType="pmc">PMC8948827</ArticleId><ArticleId IdType="pubmed">35329867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler C.X., Wyller V.B.B., Moss-Morris R., Buchwald D., Crawley E., Hautvast J., Katz B.Z., Knoop H., Little P., Taylor R., et al. Long COVID and post-infective fatigue syndrome: A review. Open Forum Infect. Dis. 2021;8:ofab440. doi: 10.1093/ofid/ofab440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab440</ArticleId><ArticleId IdType="pmc">PMC8496765</ArticleId><ArticleId IdType="pubmed">34631916</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  Nearly One in Five American Adults Who Have Had COVID-19 Still Have &#x201c;Long COVID&#x201d;.  [(accessed on 4 October 2022)]; Available online:  https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm.</Citation></Reference><Reference><Citation>Datta S.D., Talwar A., Lee J.T. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: Illness beyond acute infection and public health implications. JAMA. 2020;324:2251&#x2013;2252. doi: 10.1001/jama.2020.22717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22717</ArticleId><ArticleId IdType="pubmed">33206133</ArticleId></ArticleIdList></Reference><Reference><Citation>Darby J.B., Jackson J.M. Kawasaki disease and multisystem inflammatory syndrome in children: An overview and comparison. Am. Fam. Physician. 2021;104:244&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">34523885</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne A.B., Gilani Z., Godfred-Cato S., Belay E.D., Feldstein L.R., Patel M.M., Randolph A.G., Newhams M., Thomas D., Magleby R., et al. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw. Open. 2021;4:e2116420. doi: 10.1001/jamanetworkopen.2021.16420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.16420</ArticleId><ArticleId IdType="pmc">PMC8193431</ArticleId><ArticleId IdType="pubmed">34110391</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  Infectious Diseases Society of America. Multisystem Inflammatory Syndrome in Adults (MIS-A). Updated June 24, 2022.  [(accessed on 31 August 2022)].  Available online:  https://www.idsociety.org/covid-19-real-time-learning-network/disease-manifestations--complications/multisystem-inflammatory-syndrome-inadults-mis-a/</Citation></Reference><Reference><Citation>Nath A. Long-haul COVID. Neurology. 2020;95:559&#x2013;560. doi: 10.1212/WNL.0000000000010640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010640</ArticleId><ArticleId IdType="pubmed">32788251</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kim S.S., Lindsell C.J., Rose E.B., Shapiro N.I., Files D.C., Gibbs K.W., Erickson H.L., Steingrub J.S., Smithline H.A., et al. IVY Network Investigators; CDC COVID-19 Response Team. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network&#x2014;United States, March-June 2020. MMWR Morb. Mortal Wkly. Rep. 2020;69:993&#x2013;998. doi: 10.15585/mmwr.mm6930e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi O.L., Hughes S.E., Turner G., Rivera S.C., McMullan C., Chandan J.S., Haroon S., Price G., Davies E.H., Nirantharakumar K., et al. Symptoms, complications and management of long COVID: A review. J. R. Soc. Med. 2021;114:428&#x2013;442. doi: 10.1177/01410768211032850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., Sudre C.H., Molteni E., Bewrry S., Canas L.S., Graham M.S., Klaser K., Modat M., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: A prospective, community-based, nested, case-control study. Lancet Infect. Dis. 2022;22:43&#x2013;55. doi: 10.1016/S1473-3099(21)00460-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long COVID-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648. corrected in BMJ 2021, 374, n1944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal M., Omirah M.A., Hussein A., Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int. J. Clin. Pract. 2021;75:e13746. doi: 10.1111/ijcp.13746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.13746</ArticleId><ArticleId IdType="pmc">PMC7536922</ArticleId><ArticleId IdType="pubmed">32991035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneller M.C., Liang C.J., Marques A.R., Chung J.Y., Shanbhag S.M., Fontsana J.R., Raza H., Okeke O., Dewar R.L., Higgins B.P., et al. A longitudinal study of COVID-19 sequelae and immunity: Baseline findings. Ann. Intern. Med. 2022;175:969&#x2013;979. doi: 10.7326/M21-4905.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-4905</ArticleId><ArticleId IdType="pmc">PMC9128805</ArticleId><ArticleId IdType="pubmed">35605238</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrich W.C., Ghosh T.S., Ahearn-Ford S., Mikaeloff F., Lunjani N., Forde B., Suh N., Kleger G.-R., Pietsch U., Frischknecht M., et al. A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2. Gut Microbes. 2022;14:e2073131. doi: 10.1080/19490976.2022.2073131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2022.2073131</ArticleId><ArticleId IdType="pmc">PMC9116414</ArticleId><ArticleId IdType="pubmed">35574937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau H.C.-H., Ng S.C., Yu J. Targeting the gut microbiota in coronavirus disease 2019: Hype or hope? Gastroenterology. 2022;162:9&#x2013;16. doi: 10.1053/j.gastro.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8425294</ArticleId><ArticleId IdType="pubmed">34508775</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M., Rowntree L.C., Hensen L., Chua B.Y., van de Sandt C.E., Habel J.R., Zhang W., Jia X., Kedzierski L., Ashhurst T.M., et al. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell. Rep. Med. 2021;2:100208. doi: 10.1016/j.xcrm.2021.100208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100208</ArticleId><ArticleId IdType="pmc">PMC7862905</ArticleId><ArticleId IdType="pubmed">33564749</ArticleId></ArticleIdList></Reference><Reference><Citation>Leviatan S., Segai E. Identifying gut microbes that affect human health. Nature. 2020;587:373&#x2013;374. doi: 10.1038/d41586-020-03069-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-03069-8</ArticleId><ArticleId IdType="pubmed">33149313</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmae S., Franasiak J.M., Mandar R. The seminal microbe in health and disease. Nat. Rev. Urol. 2019;16:703&#x2013;721. doi: 10.1038/s41585-019-0250-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41585-019-0250-y</ArticleId><ArticleId IdType="pubmed">31732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Treuren W., Dodd D. Microbial contribution to the human metabolome: Implications for health and disease. Annu. Rev. Pathol. 2020;15:345&#x2013;369. doi: 10.1146/annurev-pathol-020117-043559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathol-020117-043559</ArticleId><ArticleId IdType="pmc">PMC7678725</ArticleId><ArticleId IdType="pubmed">31622559</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie P., Li Z., Wang Y., Zhang Y., Zhao M., Luo J., Du S., Deng Z., Chen J., Wang Y., et al. Gut microbiome interventions in human health and diseases. Med. Res. Rev. 2019;39:2286&#x2013;2313. doi: 10.1002/med.21584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21584</ArticleId><ArticleId IdType="pubmed">30994937</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley A., Turner J.R. Cell biology of tight junction barrier regulation and mucosal disease. Cold Spring Harb. Perspect. Biol. 2018;10:a029314. doi: 10.1101/cshperspect.a029314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a029314</ArticleId><ArticleId IdType="pmc">PMC5749156</ArticleId><ArticleId IdType="pubmed">28507021</ArticleId></ArticleIdList></Reference><Reference><Citation>Velikova T., Snegarova V., Kukov A., Batselova H., Mihova A., Nakov R. Gastrointestinal mucosal immunity and COVID-19. World J. Gastroenterol. 2021;27:5047&#x2013;5059. doi: 10.3748/wjg.v27.i30.5047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v27.i30.5047</ArticleId><ArticleId IdType="pmc">PMC8384742</ArticleId><ArticleId IdType="pubmed">34497434</ArticleId></ArticleIdList></Reference><Reference><Citation>Elizalde-Diaz J.P., Miranda-Narvaez C.L., Martinez-Lazcano J.C., Martinez-Martinez E. The relationship between chronic immune response and neurodegenerative damage in long COVID-19. Front. Immunol. 2022;13:1039427. doi: 10.3389/fimmu.2022.1039427.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1039427</ArticleId><ArticleId IdType="pmc">PMC9800881</ArticleId><ArticleId IdType="pubmed">36591299</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao B., Zhong M., Yang Q., Hong K., Xia J., Li X., Liu Y., Chen Y.Q., Yang J., Huang C., et al. Alterations in Phenotypes and Responses of T Cells Within 6 Months of Recovery from COVID-19: A Cohort Study. Virol. Sin. 2021;36:859&#x2013;868. doi: 10.1007/s12250-021-00348-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-021-00348-0</ArticleId><ArticleId IdType="pmc">PMC7871951</ArticleId><ArticleId IdType="pubmed">33560482</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>